Kaplan-Meier analyses of the subgroup of patients treated within the German AMLCG study.

(A) OS of all patients included. (B) OS of patients with normal and other karyotypes (prognostically intermediate group). (C) EFS of all patients included. (D) EFS of patients from the prognostically intermediate group. (E) DFS of all patients included. (F) DFS of patients from the prognostically intermediate group.